M
Maxime Dougados
Researcher at University of Paris
Publications - 1144
Citations - 78022
Maxime Dougados is an academic researcher from University of Paris. The author has contributed to research in topics: Rheumatoid arthritis & Ankylosing spondylitis. The author has an hindex of 134, co-authored 1054 publications receiving 69979 citations. Previous affiliations of Maxime Dougados include French Institute of Health and Medical Research & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Evaluation of Vitamin D Status in Rheumatoid Arthritis and Its Association with Disease Activity across 15 Countries: "The COMORA Study".
Najia Hajjaj-Hassouni,N. Mawani,Fadoua Allali,Hanan Rkain,Kenza Hassouni,Ihsane Hmamouchi,Maxime Dougados +6 more
TL;DR: Low levels of vitamin D were associated with patients characteristics, RA (disease activity and corticosteroid dosage), and comorbidities (lung disease and osteoporosis therapy) and suggests the need for a particular therapeutic strategy to improve vitamin D status in RA patients.
Journal ArticleDOI
Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort
Pascale Nicaise-Roland,Leonor Nogueira,C. Demattei,Luc de Chaisemartin,Nathalie Rincheval,Martin Cornillet,Sabine Grootenboer-Mignot,Philippe Dieudé,Maxime Dougados,Alain Cantagrel,Olivier Meyer,Guy Serre,Sylvie Chollet-Martin +12 more
TL;DR: Adding ACPA positivity to the 1987 ACR criteria significantly increased the number of patients classified as having RA, confirming the validity of the recent inclusion of the serological criterion in the ACR/EULAR criteria.
Journal ArticleDOI
Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials
TL;DR: The study suggests that the flare design used in clinical trials evaluating NSAIDs results in a treatment effect of higher magnitude, and should be considered when designing a trial and/or interpreting the results of a trial.
Journal ArticleDOI
OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials.
Rebecca L. Manno,Clifton O. Bingham,Simon Paternotte,Laure Gossec,H. Halhol,G. Giacovelli,Lucio C. Rovati,Steven A. Mazzuca,Daniel O. Clegg,H. Shi,E. Tajana Messi,A. Lanzarotti,Maxime Dougados +12 more
TL;DR: The prevalence of patients with sustained symptomatic OA of at least a moderate degree with X-ray progression is low and, even using lenient criteria to define VJR, large patient numbers would be required to detect differences between groups in DMOAD RCTs.
Journal ArticleDOI
Reproducibility and sensitivity to change of four scoring methods for the radiological assessment of osteoarthritis of the hand
TL;DR: The method most sensitive to change was the Kallman method, followed by Verbruggen and global scores, which suggests that structural changes could be detected in hand OA over a 1-year period.